#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Meg Alexander Email
Chief Corporate Affairs Officer . Ovid Therapeutics
How to contact Meg Alexander
Join and see Meg's contact info for free!Current Roles
Employees:
46Revenue:
$214.1MAbout
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients. Review our community guidelines: http://www.ovidrx.com/community-guidelines/Ovid Therapeutics Address
441 9th AvenueNew York, NY
United States